FDA
-
-
-
-
-
-
-
PROGENICS PHARMACEUTICALS ANNOUNCES FOURTH QUARTER AND FULL-YEAR 2019 FINANCIAL RESULTS
-
-
-
-
-
-
-
Progenics Pharma (PGNX) Phase 3 CONDOR Trial of PyL in Prostate Cancer Achieved Primary Endpoint
-
-
-
-
-
-
-
Pre-Open Movers 10/02: (VHC) (AIMT) (LEN) Higher; (SVRA) (UNFI) (AYI) Lower (more...)
-
-
-
-
-
-
-
CMS Grants New Technology Add-On Payment for Inpatient Use of AZEDRA® (iobenguane I 131)
-
-
-
-
-
-
-
Progenics Pharmaceuticals to Initiate a Basket Trial by Year End to Support an Expanded Label for AZEDRA® (iobenguane I 131) in Multiple MIBG Avid Neuroendocrine Tumors
-
-
-
-
-
-
-
Progenics Pharma (PGNX) Reports First Patient Dosing in Phase 2 Clinical Study of 1095 Radiotherapy for the Treatment of Metastatic Prostate Cancer
-
-
-
-
-
-
-
Progenics Pharmaceuticals Mails Letter to Shareholders
-
324,023 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

